Redeye provides an initial take following the release of Optomed’s Q1 2026 report. Sales came in weaker than expected, while gross margin and cost control were encouraging. Overall, we consider the report fairly weak and expect negative share price performance during the day. Furthermore, we will publish a research update in which we are likely to lower our sales estimates.
